Literature DB >> 9701492

Molecular modelling of the vasopressin V2 receptor/antagonist interactions.

C Czaplewski1, R Kaźmierkiewicz, J Ciarkowski.   

Abstract

We predict some essential interactions between the V2 vasopressin renal receptor (V2R) and its selective peptide antagonist desGly9-[Mca1,D-Ile2,Ile4]AVP, and compare these predictions with the earlier ones for the non-peptide OPC-36120 antagonist- and the [Arg8]vasopressin (AVP) agonist-V2 receptor interactions. V2R controls antidiuresis in mammals and belongs to the superfamily of the heptahelical transmembrane (7TM) G protein-coupled receptors (GPCR)s. V2R was built, the ligands docked and the structures relaxed using advanced molecular modeling techniques. Both the agonist and the antagonists (no matter whether of peptide- or non-peptide type) appear to prefer a common V2R compartment for docking. The receptor amino-acid residues, potentially important in ligand binding, are mainly in the TM3-TM7 helices. A few of these residues are invariant for the whole GPCR superfamily while most of them are conserved in the subfamily of neurohypophyseal receptors, to which V2R belongs. Some of the equivalent residues in a related V1a receptor have been earlier reported as critical for the ligand affinity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9701492

Source DB:  PubMed          Journal:  Acta Biochim Pol        ISSN: 0001-527X            Impact factor:   2.149


  6 in total

1.  Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors.

Authors:  A Giełdoń; R Kaźmierkiewicz; R Slusarz; J Ciarkowski
Journal:  J Comput Aided Mol Des       Date:  2001-12       Impact factor: 3.686

2.  Identification of avian vasotocin receptor subtype-specific antagonists involved in the stress response of the chicken, Gallus gallus.

Authors:  Seong W Kang; Srinivas Jayanthi; Gurueswar Nagarajan; Thallapuranam Krishnaswamy Suresh Kumar; Wayne J Kuenzel
Journal:  J Biomol Struct Dyn       Date:  2018-05-17

3.  Addition of vasopressin synthetic analogue [V(4)Q(5)]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models.

Authors:  Juan Garona; Marina Pifano; Maria B Pastrian; Daniel E Gomez; Giselle V Ripoll; Daniel F Alonso
Journal:  Clin Exp Metastasis       Date:  2016-05-05       Impact factor: 5.150

4.  The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models.

Authors:  Juan Garona; Marina Pifano; Ulises D Orlando; Maria B Pastrian; Nancy B Iannucci; Hugo H Ortega; Ernesto J Podesta; Daniel E Gomez; Giselle V Ripoll; Daniel F Alonso
Journal:  Int J Oncol       Date:  2015-04-03       Impact factor: 5.650

5.  Study of V2 vasopressin receptor hormone binding site using in silico methods.

Authors:  Yeganeh Sebti; Soroush Sardari; Hamid Mir Mohammad Sadeghi; Mohammad Hossein Ghahremani; Giulio Innamorati
Journal:  Res Pharm Sci       Date:  2015 Jul-Aug

6.  Effect of mutations in putative hormone binding sites on V2 vasopressin receptor function.

Authors:  Y Sebti; M Rabbani; H Mir Mohammad Sadeghi; S Sardari; M H Ghahremani; G Innamorati
Journal:  Res Pharm Sci       Date:  2015 May-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.